Program Description
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the United States. Elevated low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] are well-established, independent risk factors for ASCVD, yet maximally tolerated statin therapy fails to achieve guideline-recommended lipid targets in a substantial proportion of high-risk patients. Recurrent cardiovascular events including hospitalization continue to drive significant health care resource utilization and place a profound clinical, economic, and quality of life burden on patients and the health care system. Compounding this challenge is the widespread under-recognition of Lp(a), for which testing rates remain low even among patients with established ASCVD. This program is designed to equip managed care professionals and pharmacists with the clinical knowledge and practical tools needed to navigate the rapidly evolving lipid management landscape. The program reviews current and emerging non-statin LDL-C–lowering therapies as well as the pipeline of Lp(a)-specific agents. Updated guidance from the recently updated guidelines will frame the clinical rationale for universal Lp(a) testing and intensified lipid management in high-risk patients. With a dedicated focus on managed care strategy, the panelists will address prior authorization best practices, formulary alignment with evidence-based guidelines, and value-based care frameworks, while supporting early patient identification and empowering payers, pharmacists, and managed care organizations to translate emerging clinical evidence into improved cardiovascular outcomes.
Target audience: Managed care
pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Intermediate
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Interpret evolving guideline recommendations for comprehensive lipid management, including low-density lipoprotein cholesterol and lipoprotein(a), in patients with or at risk for atherosclerotic cardiovascular disease (ASCVD)
- Ascertain the clinical utility and value of adjunctive non-statin lipid-lowering therapies in patients who remain above treatment targets despite guideline-directed therapy
- Examine the emerging landscape of lipid-targeted therapies, including novel mechanisms of action, and their potential to address unmet needs in ASCVD prevention
- Incorporate new evidence and real-world data into payer and managed care strategies to optimize access, coverage policies, and population health outcomes in ASCVD
Joseph Saseen, PharmD, BCPS, BCACP
Professor and Associate Dean for Clinical Affairs
University of Colorado Anschutz Medical Campus
Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, CO
Ashley Teel, PharmD
Clinical Pharmacist
Pharmacy Management Consultants
University of Oklahoma College of Pharmacy
Oklahoma City, OK
Accreditation
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-098-H01-P. The activity is available for CE credit through April 30, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Ashley Teel, PharmD, has no relevant financial relationships with ineligible companies to disclose.
Joseph Saseen, PharmD, BCPS, BCACP, has the following relevant financial relationship with an ineligible company to disclose: Other Support: Member of the Amgen Data Safety Monitoring Board for Outcome Trials
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Katie Naspo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational
purposes and do not constitute any form of professional advice or referral.
Discussions concerning drugs, dosages, and procedures may reflect the clinical
experience of the author(s) or be derived from the professional literature or
other sources and may suggest uses that are investigational in nature and not
approved by the labeling or indications. Participants are encouraged to refer
to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here